Novo Nordisk A/S (NVO)
36.67
-1.09
(-2.89%)
USD |
NYSE |
Mar 03, 16:00
36.67
0.00 (0.00%)
After-Hours: 17:34
Novo Nordisk Research and Development Expense (Annual) : 6.838B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Ascendis Pharma A/S | 333.10M |
| Evaxion AS | 10.14M |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Viking Therapeutics, Inc. | 344.96M |
| DBV Technologies SA | 89.90M |